Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Cancer
    July 2026
  1. WIDICK PC, Wright AA, Liu JF
    Maintenance therapy in gynecologic malignancies: Current and future state.
    Cancer. 2026;132:e70517.
    >> Share

  2. ARENA L, Alizai Q, Elemosho A, Chatzipanagiotou OP, et al
    Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.
    Cancer. 2026;132:e70462.
    >> Share

    June 2026
  3. BARQUIN A, Kasherman L, Lheureux S, Madariaga A, et al
    Antibody-drug conjugates in gynecologic cancers.
    Cancer. 2026;132 Suppl 1:e70417.
    >> Share

    May 2026
  4. TELLES R, Thaker PH, Goodheart MJ, Penedo FJ, et al
    Rethinking depression diagnosis in ovarian cancer: The role of somatic symptoms.
    Cancer. 2026;132:e70344.
    >> Share

  5. LI L, Song N, Zhang D, Li Y, et al
    Multigene germline testing for epithelial ovarian cancer in China.
    Cancer. 2026;132:e70395.
    >> Share

  6. LAWRENCE L
    HRSA recommends offering self-collection for cervical cancer screening.
    Cancer. 2026;132:e70369.
    >> Share

    March 2026
  7. WERNER HMJ, van Dijk FAH, Vrede SW, van den Bosch AAS, et al
    The impact of the patient macroenvironment on molecular subgroups in endometrial cancer.
    Cancer. 2026;132:e70333.
    >> Share

  8. HAN K
    Advancing molecular residual disease detection in cervical cancer through next-generation sequencing of circulating human papillomavirus DNA.
    Cancer. 2026;132:e70352.
    >> Share

    February 2026
  9. TAMRAKAR VK, Sharma K, Singh P, Bhargava A, et al
    Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target.
    Cancer. 2026;132:e70292.
    >> Share

  10. BONLOKKE S, Stougaard M, Sorensen BS, Parner E, et al
    Ultrasensitive next-generation sequencing-based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring.
    Cancer. 2026;132:e70282.
    >> Share

  11. LAWRENCE L
    Immunochemotherapy regimen demonstrates survival benefits for patients with platinum-resistant ovarian cancer.
    Cancer. 2026;132:e70251.
    >> Share


  12. Correction to "Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial".
    Cancer. 2026;132:e70324.
    >> Share

  13. SHAN Y, Ding B, Ji F, Lin H, et al
    T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cancer.
    Cancer. 2026;132:e70279.
    >> Share

  14. O'CONNELL CP, Berndt SI, Chudy-Onwugaje K, Kunzmann A, et al
    Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Cancer. 2026;132:e70201.
    >> Share

    January 2026
  15. LAWRENCE L
    Adjuvant chemoradiation offers minimal survival improvements over radiation alone in intermediate-risk, early cervical cancer: Chemoradiation has become the standard of care for patients with locally advanced cervical cancer as well as high-risk featu
    Cancer. 2026;132:e70207.
    >> Share

  16. CHOI HL, Kim B, Mark Park YM, Yoo JE, et al
    Metabolic obesity phenotypes and breast cancer risk before and after menopause: A nationwide cohort study in South Korea.
    Cancer. 2026;132:e70244.
    >> Share

    November 2025
  17. YE Z, Zhao Y, Wang J, Wang Q, et al
    Pooled performance of urinary human papillomavirus (HPV) testing for the presence of cervical HPV.
    Cancer. 2025;131:e70175.
    >> Share

  18. FITCH KC, Yang JC, Ryan ES, Monuszko KA, et al
    Preferences of BRCA mutation carriers for attributes of risk-reducing surgical options for breast and ovarian cancer.
    Cancer. 2025;131:e70148.
    >> Share

    October 2025
  19. LIN KY, Farley JH
    Putting a spotlight on current chemotherapeutic options for recurrent ovarian clear cell carcinoma.
    Cancer. 2025;131:e70112.
    >> Share

    September 2025
  20. YOSHINO Y, Furusawa A, Nara K, Taguchi A, et al
    Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab.
    Cancer. 2025;131:e70071.
    >> Share

    August 2025
  21. VISTAD I, Skorstad M, Berntsen S, Demmelmaier I, et al
    Empowerment and quality of life in gynecological cancer survivors: Outcomes from a multicenter quasi-experimental cohort study from Norway (the LETSGO trial).
    Cancer. 2025;131:e70040.
    >> Share

  22. MACDUFFIE E, McCallister C, George J, Monare B, et al
    Assessing the impact of multidisciplinary team gynecological oncology care in Botswana: A potential model for low- and middle-income countries.
    Cancer. 2025;131:e70006.
    >> Share

    July 2025
  23. FONTVIEILLE E, Jansana A, Peruchet-Noray L, Cordova R, et al
    Body mass index and breast cancer risk among postmenopausal women with and without cardiometabolic diseases: Findings from two prospective cohort studies in Europe.
    Cancer. 2025;131:e35911.
    >> Share

    May 2025
  24. DUSKA LR, Lim J, Calderon Boyle TA, Guinter M, et al
    The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
    Cancer. 2025;131:e35821.
    >> Share

  25. SCHNEIDER DT, Witowski A, Abele M, Benesch M, et al
    Testicular and ovarian Juvenile granulosa cell tumors in children and adolescents: Analysis of 113 patients registered to the German Registry for Rare Pediatric Tumors (STEP).
    Cancer. 2025;131:e35861.
    >> Share

  26. HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al
    Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.
    Cancer. 2025;131:e35862.
    >> Share

  27. EBOTT J, Grant KR, Farley J, Stasenko M, et al
    Gender equity gap persists, addressing the root cause through the lens of gynecologic oncology: An evidenced-based review.
    Cancer. 2025;131:e35843.
    >> Share

  28. HUANG CC, Ayala-Peacock DN, Stephens SJ, Chino JP, et al
    Recent advances in gynecologic radiation oncology.
    Cancer. 2025;131:e35888.
    >> Share

    April 2025
  29. KUNOS CA, Chauhan A
    Prospects for radioimmunotherapy panaceas in gynecologic oncology.
    Cancer. 2025;131:e35841.
    >> Share

  30. FREY MK, Liu JF
    Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancer.
    Cancer. 2025;131:e35800.
    >> Share

  31. APPLEBAUM JC, Ginsburg ES
    Parenthood after cancer: The critical, yet complex, contribution of gestational carriers.
    Cancer. 2025;131:e35853.
    >> Share

  32. ELLINGTON TD, Wardell AC, Deal AM, Mersereau J, et al
    In vitro fertilization with cryopreserved oocytes or embryos after cancer: The role of gestational carriers.
    Cancer. 2025;131:e35844.
    >> Share

    March 2025
  33. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    >> Share

  34. KARPEL HC, Zambrano Guevara LM, Rimel BJ, Hacker KE, et al
    The missing data: A review of gender and sex disparities in research.
    Cancer. 2025;131:e35769.
    >> Share

  35. SOROURI K, Glass K, Ruddy KJ, Warner E, et al
    Anti-Mullerian hormone for assessing ovarian toxicity of cancer treatment in young women: It's complicated.
    Cancer. 2025;131:e35774.
    >> Share

  36. BAE HS, Temkin SM
    Cervical cancer stigma - A silent barrier to the elimination of cervical cancer.
    Cancer. 2025;131:e35776.
    >> Share

  37. NIERENGARTEN MB
    More evidence on benefits of HIPEC for recurrent ovarian cancer.
    Cancer. 2025;131:e35754.
    >> Share

    February 2025
  38. PENNINX BMF, Samson MJ, Schnog JB
    Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?
    Cancer. 2025;131:e35749.
    >> Share

  39. DUSKA LR, Petroni GR, Thaker PH, Crane EK, et al
    Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
    Cancer. 2025;131:e35757.
    >> Share

  40. NIERENGARTEN MB
    New standard of care for patients with locally advanced cervical cancer.
    Cancer. 2025;131:e35739.
    >> Share

  41. BAEKER BISPO J, Jemal A, Islami F
    Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression.
    Cancer. 2025;131:e35724.
    >> Share

  42. HIPPALGAONKAR N, Huo D, Hoskins KF
    The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome.
    Cancer. 2025;131:e35722.
    >> Share

  43. NERO C, Trozzi R, Persiani F, Rossi S, et al
    POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center cohort.
    Cancer. 2025;131:e35731.
    >> Share

  44. TEMKIN SM
    Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer.
    Cancer. 2025;131:e35735.
    >> Share

    January 2025
  45. REN W, Guo X, Liu Z, Wu Y, et al
    Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Cancer. 2025;131:e35712.
    >> Share

  46. LIU YL, Mathews CA, Simpkins F, Cadoo KA, et al
    Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.
    Cancer. 2025;131:e35707.
    >> Share

  47. NIERENGARTEN MB
    Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high-risk locally advanced cervical cancer.
    Cancer. 2025;131:e35688.
    >> Share

  48. MAHALINGAM D, Owonikoko TK, Delpassand E, Mulcahy MF, et al
    A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
    Cancer. 2025;131:e35680.
    >> Share

  49. RICHARDS AR, Johnson CE, Montalvo NR, Alberg AJ, et al
    Comorbid conditions and survival among Black women with ovarian cancer.
    Cancer. 2025;131:e35694.
    >> Share

  50. PANDEY AS, Drogan C, Huo D, Postula K, et al
    Anticipation in families with MLH1-associated Lynch syndrome.
    Cancer. 2025;131:e35589.
    >> Share

    December 2024
  51. HENDRIX EL, Chollette VY, Wentzensen N, Loukissas JK, et al
    Federal Cervical Cancer Collaborative: Improving cervical cancer prevention through vaccination, screening, and management in safety-net settings of care.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35655.
    >> Share

    November 2024
  52. NIERENGARTEN MB
    Common strategy to diagnose endometrial cancer may not be reliable for Black women.
    Cancer. 2024;130:3783.
    >> Share

  53. NIERENGARTEN MB
    Women with more severe forms of endometriosis have a nearly 10-fold higher risk of ovarian cancer.
    Cancer. 2024;130:3784.
    >> Share

    October 2024
  54. KONDO T, Matsuki E, Takaku T, Watanabe N, et al
    Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35611.
    >> Share

  55. JOHNSON HM, Song J, Warneke CL, Martinez AL, et al
    Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy.
    Cancer. 2024 Oct 29. doi: 10.1002/cncr.35619.
    >> Share

  56. WILSON EM, Huang R, Jones KD, Hagemann IS, et al
    Challenges in implementation of molecular classification in early stage endometrial cancer-An NRG Oncology cooperative group mixed-methods study.
    Cancer. 2024 Oct 17. doi: 10.1002/cncr.35596.
    >> Share

  57. NIERENGARTEN MB
    Excellent outcomes with radiation alone for localized recurrences of endometrial cancer.
    Cancer. 2024;130:3400.
    >> Share

    September 2024
  58. MEGHANI K, Grover S
    Reply to "Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary".
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35553.
    >> Share

  59. JEYARAJ G
    Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary.
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35545.
    >> Share

    August 2024
  60. SULLIVAN MW, Graves S, Adkoli A, Zhou Q, et al
    Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.
    Cancer. 2024 Aug 16. doi: 10.1002/cncr.35523.
    >> Share

  61. ISSAKA RB, Ibekwe LN, Todd KW, Burnett-Hartman AN, et al
    Association between racial residential segregation and screening uptake for colorectal and cervical cancer among Black and White patients in five US health care systems.
    Cancer. 2024 Aug 9. doi: 10.1002/cncr.35514.
    >> Share

    July 2024
  62. PEREZ L, Dioun S, Primiano M, Blank SV, et al
    Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening.
    Cancer. 2024 Jul 22. doi: 10.1002/cncr.35480.
    >> Share

  63. MACKAY H, Fernandes I
    Cell-free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35448.
    >> Share

  64. ELGHAZALY H, Azim HA, Rugo HS, Cameron D, et al
    Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35389.
    >> Share

  65. BANERJEE S, Hasson SP
    Top advances of the year: Immunotherapy in endometrial cancer.
    Cancer. 2024 Jul 4. doi: 10.1002/cncr.35417.
    >> Share

  66. NIERENGARTEN MB
    Significant overall survival benefit with dostarlimab plus chemotherapy in advanced endometrial cancer.
    Cancer. 2024;130:2245.
    >> Share

  67. NIERENGARTEN MB
    Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer.
    Cancer. 2024;130:2246.
    >> Share

    June 2024
  68. BEAVIS AL, Wethington SL, Yu R, Topel KM, et al
    Differential utilization of the online patient portal for completion of health-related social needs screening during routine gynecologic cancer care.
    Cancer. 2024 Jun 29. doi: 10.1002/cncr.35376.
    >> Share


  69. Erratum to "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials".
    Cancer. 2024 Jun 7. doi: 10.1002/cncr.35344.
    >> Share

  70. BLANC-DURAND F, Camilleri GM, Bayle A, Aldea M, et al
    Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
    Cancer. 2024 Jun 2. doi: 10.1002/cncr.35381.
    >> Share

    May 2024
  71. LOGGERS ET, Chugh R, Federman N, Hartner L, et al
    Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
    Cancer. 2024 May 4. doi: 10.1002/cncr.35324.
    >> Share

    April 2024
  72. DUSKA LR, Podwika SE, Randall LM
    Top advances of the year: Cervical cancer.
    Cancer. 2024 Apr 23. doi: 10.1002/cncr.35334.
    >> Share

  73. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    >> Share

  74. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    >> Share

  75. NIERENGARTEN MB
    Promising new treatment approaches for locally advanced cervical cancer.
    Cancer. 2024;130:1192.
    >> Share

  76. ERICKSON BK, Slomovitz B, Powell M, Eskander RN, et al
    Top advances of the year: Uterine cancer.
    Cancer. 2024 Apr 15. doi: 10.1002/cncr.35321.
    >> Share

    March 2024
  77. MEGHANI K, Puri P, Bazzett-Matabele L, Vuylsteke P, et al
    Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35289.
    >> Share

  78. LEE H, Baeker Bispo J, Pal Choudhury P, Wiese D, et al
    Factors contributing to differences in cervical cancer screening in rural and urban community health centers.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35265.
    >> Share

  79. MICHEL AD, Fontenot HB, Fuzzell L, Brownstein NC, et al
    Attitudes toward the American Cancer Society's 2020 cervical cancer screening guidelines: A qualitative study of a national sample of US clinicians.
    Cancer. 2024 Mar 4. doi: 10.1002/cncr.35269.
    >> Share

    February 2024
  80. LIU YL, Weigelt B
    A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35267.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016